Coming soon
CagriSema
10mg · Single vial · Lyophilized powder
- Dose
- 10mg
- Pack size
- Single vial
- Form
- Lyophilized powder
- Storage
- 2–8°C
In vitro laboratory research use only · Not for human or veterinary use · Batch documented · Third-party tested · Ships from Canada
§ Research
Research · CagriSema
Overview
CagriSema is a fixed co-formulation of two long-acting agonists developed by Novo Nordisk: cagrilintide, an acylated amylin analog that activates amylin and calcitonin receptors, and semaglutide, a GLP-1 analog with a C-18 fatty diacid side chain. Both components bind albumin and have half-lives of approximately one week, allowing them to be combined in a single formulation. The combination is investigated as a model of dual amylin and GLP-1 receptor agonism in metabolic research.
Mechanism of action
The two components act through distinct receptor systems. Cagrilintide activates amylin receptors (calcitonin receptor and receptor activity-modifying protein heterodimers) in the area postrema and hypothalamus, which is associated with enhanced satiation, slowed gastric emptying, and suppression of postprandial glucagon. Semaglutide activates the GLP-1 receptor in pancreatic beta cells, the gastrointestinal tract, and the central nervous system, stimulating glucose-dependent insulin secretion, suppressing glucagon, and modulating appetite circuits. Engagement of both pathways is proposed to produce additive effects on energy intake.
Key research findings
- 01
Each component has its own published literature: cagrilintide as a long-acting amylin analog and semaglutide as a reference GLP-1 receptor agonist.
- 02
A phase 1b study characterized safety, tolerability, and pharmacokinetics when cagrilintide was co-administered with semaglutide, with no clinically relevant pharmacokinetic interaction between the components.
- 03
A phase 2 trial in participants with type 2 diabetes characterized glycated hemoglobin and body weight endpoints for the combination relative to each component alone.
- 04
The phase 3 REDEFINE program characterized body weight and cardiometabolic endpoints in participants with and without type 2 diabetes, with gastrointestinal events as the most frequently reported adverse events.
Published references
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
The information above is derived from published preclinical and clinical research. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.